Welche PD-Lösung bei Peritonealdialyse?

Die Peritonealdialyse (PD) wird im Vergleich zur Hämodialyse (HD) weltweit weiterhin seltener eingesetzt. Gegen den Einsatz der PD spricht, dass auftretende Langzeitkomplikationen das Verfahren nur für wenige Jahre ermöglichen und dann eine Umstellung auf HD erfolgen muss, um das Leben der Patienten nicht zu gefährden. Neuere Ansätze gehen davon aus, dass bei gezieltem Einsatz der PD-Lösungen die Langzeitkomplikationen besser beherrschbar werden und damit der Einsatz einer PD für mehr Patienten länger gut vertretbar ist. Das Hauptproblem ist die zurückgehende Ultrafiltration.

• Literatur

• 1 Honda K, Nitta K, Horita S. et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549
• 2 Williams JD, Craig KJ, Topley N. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
• 3 Alscher DM, Braun N, Biegger D. et al. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007; 49: 452-461 doi:10.1053/j.ajkd.2006.11.040
• 4 Davies SJ, Phillips L, Naish PF. et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046-1051
• 5 Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66: 2437-2445 doi:10.1111/j.1523–1755.2004.66021.x
• 6 Rippe B, Venturoli D. Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model. Am J Physiol Renal Physiol 2007; 292: F1035-1043 doi:10.1152/ajprenal.00251.2006
• 7 Braun N, Reimold F, Biegger D. et al. Fibrogenic growth factors in encapsulating peritoneal sclerosis. Nephron Clin Pract 2009; 113: c88-c95 doi:10.1159/000228540
• 8 Ates K, Nergizoglu G, Keven K. et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776 doi:10.1046/j.1523–1755.2001.060002767.x
• 9 Schwenger V, Morath C, Salava A. et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207 doi:10.1681/ASN.2005020155
• 10 Mortier S, Faict D, Lameire NH. et al. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67: 1559-1565 doi:10.1111/j.1523–1755.2005.00237.x
• 11 Erixon M, Wieslander A, Linden T. et al. How to avoid glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 2006; 26: 490-497
• 12 Alscher DM, Pauli-Magnus C, Kirchgessner J. et al. A new lactate-based, plasticizer-free, neutral peritoneal dialysis fluid provided in a two-compartment system: effect on peripheral leukocyte function. Nephron 2000; 86: 62-69 doi:10.1159/000045714
• 13 Lee HY, Choi HY, Park HC. et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21: 2893-2899 doi:10.1093/ndt/gfl393
• 14 Han SH, Ahn SV, Yun JY. et al. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009; 54: 711-720 doi:10.1053/j.ajkd.2009.05.014
• 15 Williams JD, Topley N, Craig KJ. et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418 doi:10.1111/j.1523–1755.2004.00747.x
• 16 Haag-Weber M, Kramer R, Haake R. et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010; 25: 2288-2296 doi:10.1093/ndt/gfq087
• 17 Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162
• 18 Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?. Nephrol Dial Transplant 2009; 24: 2620-2622 doi:10.1093/ndt/gfp313
• 19 Jansen MA, Hart AA, Korevaar JC. et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053 doi:10.1046/j.1523–1755.2002.00505.x
• 20 Jansen MA, Termorshuizen F, Korevaar JC. et al. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005; 68: 1199-1205 doi:10.1111/j.1523–1755.2005.00512.x
• 21 Schaefer B, Bartosova M, Macher-Goeppinger S. et al. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int 2018; 94: 419-429 doi:10.1016/j.kint.2018.02.022